Drug Trial Radar · NCT01243411
A Study of AA4500 in Men With Peyronie's Disease
Last checked: Nov 20, 2026Latest source record: Oct 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
348
Actual
Start
Nov 2010
Primary completion
Aug 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics CompanyIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug in the first treatment cycle. After up to four treatment cycles, each subject will be followed for additional safety and efficacy assessments on Days 168 (± 7 days) and 252 (± 7 days) (nominal weeks 24 and 36). After the final injection of each treatment cycle, the investigator will model the plaque in an attempt to stretch or elongate the plaque. If the subject's penile curvature is reduced to \<15° after the first, second, or third cycle of injections or if the investigator determines further treatment is not clinically indicated (eg, adverse events; allergic reaction), subsequent treatment cycles will not be administered. Approximately 300 subjects will be enrolled.
Conditions
- Peyronie's Disease
Interventions
AA4500Biological
2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change From Baseline in Penile CurvatureTime frame: Baseline and Week 36
- Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)Time frame: Baseline and Week 36
Locations
39 sites in 9 countries. Site status is shown where the registry gives one.
Urology Associates Medical Group
Burbank, California
Connecticut Clinical Research Center, LLC
Middlebury, Connecticut
The Urology Center, P.C.
New Haven, Connecticut
South Florida Medical Research
Aventura, Florida
Urology Specialists, S.C.
Chicago, Illinois
Northeast Indiana Research, LLC
Fort Wayne, Indiana
Metropolitan Urology, P.S.C.
Jeffersonville, Indiana
Maimonides Medical Center, Division of Urology
Brooklyn, New York
University Urology Associates
New York, New York
Tristate Urologic Services PSC, Inc./ dba TUG Research
Cincinnati, Ohio
Urologic Consultants of SE PA
Bala-Cynwyd, Pennsylvania
Urology of Virginia-Sentara Medical Group
Norfolk, Virginia
Virginia Urology
Richmond, Virginia
Aarhus Universitiy Hospital, Aalborg Sygehus
Aalborg, Denmark
Frederiksberg Hospital
Frederiksberg, Denmark
Frederikssunds Hospital
Frederikssund, Denmark
Klinik for seksuelle dysfunktioner
Gentofte Municipality, Denmark
Centre Hospitalier Edouar Herriot
Lyon, France
Hopital Henri Gabrielle
Saint-Genis-Laval, France
Universitatsklinikum Freiburg, Abteilung Urologie
Freiburg im Breisgau, Germany
Private Practice of Urology/Andrology
Hamburg, Germany
Uro-Onkologische Praxis Dr. von Keitz
Marburg, Germany
Urologische Gemeinschaftspraxis Reutlingen
Reutlingen, Germany
Universitatsklinikum Tubingen
Tübingen, Germany
University of Naples "Federico II"
Naples, Italy
Universitiy Tor Vergatat of Rome
Rome, Italy
Waitemata Urology Research North Shore Hospital
Takapuna, Auckland, New Zealand
Tauranga Urology Research Ltd.
Tauranga, Bay of Plenty, New Zealand
Primorus Clinical Trials Ltd.
Christchurch, Canterbury, New Zealand
CURT Medical Trials Trust Board Inc.
Christchurch, Canterbury, New Zealand
Cardinal Points Research Ltd.
Whangarei, Northland, New Zealand
Wellington Urology Associates
Wellington South, Wellington Region, New Zealand
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital La Zarzuela
Madrid, Spain
Specialistmottagningen i urologi
Gothenburg, Sweden
Carlshamns Specialistklinik
Karlshamn, Sweden
Akademiska Sjukhuse
Uppsala, Sweden
St. Peter's Andrology Centre
London, United Kingdom
Sunderland Royal Hospital
Sunderland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.